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UnsuitabilityToxicities resulting from platinum based chemotherapy in head and neck cancer is a cause for much
concern. There is a lack of clinical criteria for defining these patient populations, which has posed serious
problems associated with increased morbidity and consequently an adverse effect on patients’ quality of
life. In addition, there is a lack of consensus on clinical criteria for defining such patient populations, who
may be unsuitable for concurrent chemoradiotherapy. A group of experts in the field of head and neck
cancer from the Asia Pacific Region convened in August 2014 in Korea to discuss the development of a
set of clinical criteria in order to fill the knowledge gap and provide a reference tool for head and neck
oncologists. This paper reports the final output from this meeting and the accompanying literature
review, with the aim of aiding clinical decision making with the help of some clinical criteria to identify
platinum unsuitable patient populations in head and neck cancer management. Some alternative treat-
ment options are also discussed in this paper.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Background
Squamous cell carcinoma of the head and neck (SCCHN)
accounts for 6% of all malignancies. There are an estimated
686,000 new head and neck cancer cases and 376,000 related
deaths per year worldwide [1]. The majority of SCCHN patientsare diagnosed with loco-regional disease, while 10% of patients
present with metastatic disease from the start [2].
The MACH-NC analysis (meta-analysis of chemotherapy in head
and neck cancer) demonstrated a 6.5% absolute improvement in
5-year overall survival with concurrent chemo-radiotherapy
(CCRT) over radiotherapy (RT) alone. Concurrent high-dose cis-
platin (100 mg/m2 on days 1, 22 and 43 during RT) was identified
as the most effective regimen [3]. Definitive CCRT, with high-dose
cisplatin, is therefore regarded as the preferred choice in the
European and NCCN clinical practice guidelines for the treatment
of fit patients with loco-regionally advanced SCCHN (LA-SCCHN)
[4,5].
M.-J. Ahn et al. / Oral Oncology 53 (2016) 10–16 11However, platinum-based CCRT is hampered by acute and late
toxic effects, and in particular the late toxicity has major implica-
tions for the quality of life of the cancer survivors. This becomes an
even more severe problem when cisplatin-based induction
chemotherapy is followed by cisplatin-based CCRT. Issues relating
to cumulative toxicity concerns with this latter approach place
restrictions on its routine use as a standard form of treatment in
LA-SCCHN. It is worthy of note that in a multivariate analysis of
three studies in which patients were treated with CCRT, older
age, advanced tumor stage, larynx/hypopharynx primary site, and
neck dissection following CCRT proved to be strong independent
risk factors in predicting severe late toxicity and complications
[6]. Methods to reduce the toxicity of cisplatin-based CCRT include,
among others, better radiation targeting, the use of newer radio-
therapy techniques, and alternatives to the use of high-dose cis-
platin. Based on the earlier mentioned MACH-NC meta-analysis
the use of carboplatin/5-fluorouracil is an accepted alternative,
both in Europe and in the US. For all other approaches, there is cur-
rently uncertainty regarding the best choice for concomitant
agents. That is also the case for patients in whom cisplatin may
be contraindicated, such as in those with pre-existing auditory
problems, peripheral neuropathy and/or renal dysfunction. How-
ever, sufficiently large phase III trials of low-dose weekly cisplatin
or other cytotoxic agents versus standard high-dose cisplatin dur-
ing RT are lacking, and therefore these approaches have not
reached the same level of recommendation.
As for the use of cetuximab as an alternative to high-dose cis-
platin, the recommendations in Europe differ from those formu-
lated in the NCCN guidelines. There has been no randomized
phase III trial reported that compares cetuximab/RT with
cisplatin-based CCRT and the only data available are those reported
from a phase III trial, comparing cetuximab/RT with RT alone [7],
and from a randomized phase II study, comparing cetuximab/RT
with cisplatin-based CCRT after cisplatin-based induction
chemotherapy [8]. In addition, a recently published literature-
based meta-analysis on platinum-based CCRT versus cetuximab/
RT showed significantly better 2-year results with respect to over-
all survival, progression-free survival and loco-regional control [9].
The lack of sufficient data addressing these issues confounds deci-
sion making. Yet, the choice for the most optimal treatment for an
individual patient is a critical issue and therefore a better selection
of patients who might need less aggressive therapy versus those
who might need more is another important area of research [10–
12].
With quality of life being an important aspect while considering
treatment options, a risk based approach toward appropriate
patient selection is crucial as not all patients may require exposureTable 1
Gaps in existing criteria.
Excerpt from NICE guidelines G
1.1 Cetuximab in combination with radiotherapy is recommended as a treat-
ment option only for patients with LA SCCHN whose Karnofsky perfor-
mance status (KPS) score is 90% or greater and for whom all forms of
platinum based chemo-radiotherapy treatment are contraindicated
1
1.2 Patients currently receiving cetuximab in combination with radiotherapy
for the treatment of LA SCCHN who do not meet the criteria outlined in
section 1.1 should have the option to continue therapy until they and
their clinicians consider it appropriate to stop
2
1.3 When using Karnofsky performance status score, clinicians should be
mindful of the needs to secure equality of access to treatment for patients
with disabilities. Clinicians should bear in mind that people with disabil-
ities may have difficulties with activities of daily living that are unrelated
to their prognosis with respect to cancer of the head and neck. In such
cases clinicians should make appropriate judgment of performance status
taking into account the person’s usual functional capacity and require-
ment for assistance with activities of daily living
3to highly cytotoxic therapy, e.g. young patients with HPV (human
papillomavirus) positive oropharyngeal cancers and no history of
regular smoking [13].
As may be seen from the NICE UK guidelines, knowledge gaps
exist (Table 1) in defining criteria for platinum intolerance or
increased toxicity in at-risk patients with LA SCCHN [14].
Given to understand the potential gaps in guidelines (Table 1)
versus their clinical interpretation, we may explain the reason for
some cause for ambiguity and likelihood of misinterpretation of
these guidelines when approaching patients in the management
of head and neck cancer. In the absence of any literature that
clearly defines the category of platinum unsuitable patients, it
therefore becomes essential for the formulation of consensus
guidelines among head and neck experts after appropriate litera-
ture review in establishing clear and definitive clinical criteria in
this group of patients with LA-SCCHN.
Summary of short and long-term impact of treatment related toxicities
Cisplatin, or cis-diamminedichloroplatinum (II) can react
in vivo, binding to and causing crosslinking of DNA, which ulti-
mately triggers apoptosis [15]. As for the metabolism of cisplatin,
total platinum declines tri-exponentially (t1/2c = 4–6 days) and
its half-life will further increase later on. Free platinum, which is
central to the anti-tumor activity, declines in biphasic manner
(t1/2b = 40 min). Maximum platinum levels of 0.51–0.58 lg/ml
(in 90–150 min) in red blood cells (RBCs) can be reached after
administration of 100 mg/m2 cisplatin. About 30% can be excreted
from the body within 24 h [16,17].
Most toxicities are dose and schedule dependent, with shorter
infusions inducing earlier and more severe toxicity than slow infu-
sions, suggesting that some of the toxicities are peak-dose depen-
dent. Nausea and vomiting are common. Renal insufficiency is
cumulative, can be ameliorated by hydration, but cannot be com-
pletely prevented. The symptoms of neurotoxicity typically occur
after a cumulative dose of 300 mg/m2; and the symptoms begin
and often progress up to 4 months after stopping cisplatin; in
30–50% of patients neurotoxicity is irreversible. Ototoxicity is
cumulative and irreversible. Other toxicities include myelosup-
pression, liver toxicity with increased transaminases, and pyrexia.
Rare toxicities may comprise hypersensitivity, visual impairment,
hemolytic anemia, Raynaud’s syndrome, hypertension, cardiac
events and microangiopathy.
All reasonable precautions should be taken when using cis-
platin, such as avoiding use of other nephrotoxic drugs e.g.
aminoglycosides, monitoring electrolytes (Mg2+ and Ca2+), and
maintaining high urine flow during therapy. Aggressiveaps in criteria
. Recommendation 1.1 mentions platinum unsuitable patients, but fails to
define clear criteria for contraindications and intolerance to platinum observed
in practice
. Recommendation 1.1 states that patients with a KPS score ofP90% are eligible
for cetuximab plus radiotherapy (RT), and Recommendation 1.3 further stres-
ses the use of this scoring method. However in real practice, it is patients with
poor PS who receive cetuximab + RT
. Patients who have received cisplatin based induction therapy may be not suit-
able for concomitant chemo-radiotherapy in the definitive phase due to cumu-
lative toxicity. However this commonly practiced protocol is not covered in the
Recommendations
Closed dots: patients who received 350-450 mg/m² cisplatin 
 Open dots: patients who received 600-950 mg/m² cisplatin 
Fig. 2. Circulating plasma platinum >10 years after cisplatin treatment for testic-
ular cancer.
12 M.-J. Ahn et al. / Oral Oncology 53 (2016) 10–16antiemetic treatment, i.e. the triple regimen [5-HT3 RAs (5-
hydroxytryptamine receptor antagonists), corticosteroids, and
NK1RAs (neurokinin 1 receptor antagonists)] can be helpful; and
full high dose of cisplatin is usually administered only in case of
a creatinine clearance (CCR) of P60 ml/min.
A study in which cisplatin was administered at different
dosages by rapid infusion revealed that the binding of platinum
to both plasma and proteins and RBCs in vitro (using patients’
own blood) was slow, biphasic, and irreversible [16]. Another study
compared three different infusion schedules, i.e. the rapid infusion,
3-hour infusion or 24-hour infusion, while the same dose of cis-
platin was used throughout. Peak plasma concentrations differed
substantially (both total and free platinum species) and, as men-
tioned earlier, this may have implications with respect to some
of the toxicities that patients may experience. On the other hand,
the area under the concentration-time curves (AUC) of the free
platinum species (the active component) proved to be comparable
to each other and independent of the infusion schedule, when cis-
platin was given at the same dose [18]. This might suggest that
irrespective of the infusion schedule, cisplatin administered at
the same dose would produce the same level of anti-tumor activ-
ity. Prolonged infusions may therefore lead to less toxicity than
rapid infusions.
A study on ototoxicity showed that the incidence of audio-
graphic changes increased with increasing cumulative cisplatin
dose independent of the treatment schedule. The incidence corre-
lated with the daily dose (P = 0.0037) and changes were more sev-
ere after single high doses [19]. Patients with preexisting hearing
loss were at higher risk of suffering from deafness at a later time.
In that study it became evident from an analysis performed in
patients treated with the so-called LD5 regimen, i.e. 20 mg/
m2/day for 5 days, that age did have an influence on the develop-
ment of ototoxicity (P = 0.041). Older patients were more suscepti-
ble to more severe ototoxicity (Fig. 1).
Long-term toxicity in patients after cisplatin-based chemother-
apy, especially cardiovascular risk factors [20], does take place as
cisplatin can adhere to all tissues for a long time (Fig. 2) [21]. Even
20 years after cisplatin-based chemotherapy, platinum can still be
found in plasma.
Objectives
In view of the above literature review, existing PK-PD (pharma
cokinetic-pharmacodynamic) data from basic and extensive
research and the unmet need for clinical criteria to define platinum
unsuitable patient populations, an Expert Panel meeting was held
in South Korea to identify patient populations who may be ineligi-Fig. 1. Incidence of audio-graphic changes in relation to cumulative cisplatin dose
in patients of different age categories.ble for platinum based therapy or at high risk of severe acute and
late toxicities after platinum based treatment in SCCHN.
Platinum unsuitable patients are defined as those in whom plat-
inum based chemotherapy is either contraindicated or leads to
increased risk of toxicity. Correspondingly, the clinical practice rec-
ommendations developed in this paper will focus on: (1) criteria
for defining platinum intolerance and contraindications; (2) crite-
ria for defining at-risk populations who receive cisplatin.
Methodology
Structure of the expert panel meeting
The Panel members were composed of experts with substantial
experience in medical, radiation and surgical oncology from Bel-
gium, India, Korea, Hong Kong, Mainland China, Australia, Vietnam,
Taiwan and Thailand. They convened to discuss the clinical recom-
mendations and criteria for defining platinum ineligibility in
patient populations with head and neck cancer. The Expert Panel
meeting followed the Delphi principle of consensus development,
wherein the experts were adequately updated on the topic, with
a summary of the available literature. In addition, the experts were
given room to exchange clinical experience to achieve a practical
and pragmatic solution to the unmet needs identified.
Method of discussion
Following a presentation on evidence and research outcomes to
identify platinum unsuitable patient populations in head and neck
cancer, the Expert Panel was split into two groups (Fig. 3) in order
for panel members to list clinical criteria for, respectively, con-
traindications to platinum (Group A) and cases at high risk of plat-
inum toxicities (Group B). It was advised that a balance should be
achieved between literature evidence and real-life clinical practice.
Method for forming consensus/recommendations
Two representatives, nominated by their respective groups, pre-
sented back the results to the Panel on behalf of Group A and B, and
a senior distinguished oncologist moderated the Panel discussion
session to spark in-depth debate on various contentious issues.
The concept of absolute contraindications was put forward to avoid
overlap between Group A and B.
All participants
Group A:
Brainstorming: listing 
clinical criteria for 
contraindications to 
platinum
Group B:
Brainstorming: listing
clinical criteria for 
identifying cases at high risk 
of platinum toxicities 
following prescription 
All participants
Presenting back  
Panel discussion and consensus development 
Fig. 3. Workflow for group discussion.
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life-threatening conditions. A procedure or medication that falls
under this category should be avoided. On the other hand, high risk
means that caution should be taken when a procedure or medica-
tion is being used.
Consensus and recommendations
In accordance with the findings from the literature review the
Panel members listed as many items as possible by brainstorming.
These items were re-categorized during the panel discussion
session following reaching an agreement among PanelTable 2
Finalized outputs of Group A. Clinical criteria for absolute contraindications to cisplatin.
Listing items
(physiological system/
clinical condition)
Rationale Clinical/laboratory paramet
Performance status Poor compliance ECOG score P3
Renal dysfunction Worsening of toxicity CCR <50 ml/min
Risk of fluid overload or
dehydration
Correlating with ototoxicity
Otologic disorders Permanent hearing
impairment affecting quality
of life
Medical history: pre-existin
Abnormal audiometry withi
threshold shift > 25 dB aver
hearing loss but hearing aid
Neurologic disorders Neuropathy Pgrade 2 (e.g. diabetic neu
orthostatic hypotension, Lhe
encephalopathy)
Known
hypersensitivity to
platinum based
therapy
Unforeseen reactions Allergic to agents that conta
cardiovascular and respirato
Pregnancy and
lactation
Adversely affecting
embryogenesis, increased
risk of fetal toxicities
Avoiding pregnancy
Breast feeding not recomme
HIV/AIDS Weakening of immune
system
WHO definition: CD4 countmembers. The final output of Group A and B is summarized in
Tables 2 and 3.
Criteria for contraindications to platinum exposure
Consensus was reached that cisplatin should not be used in
patients who have the following characteristics: a performance
status ECOG (Eastern Cooperative Oncology Group) score of grade
3 or higher, organ dysfunction of grade 2 or higher based on the
NCI CTC (National Cancer Institute Common Toxicity Criteria) ver-
sion 4.0 [22], such as hearing loss and tinnitus and neurologic dis-
orders, hypersensitivity to platinum, pregnancy and lactation, CD4
count less than 200/ll in HIV/AIDS patients. As for renal function,
the Panel reached consensus on a cut-off glomerular filtration rate
(GFR) value of 50 ml/min/BSA (body surface area) 1.73 m2 (or a
CCR value of <50 ml/min), although a cutoff CCR value of <60 ml/
min was generally used to determine ineligibility for high-dose
cisplatin-based chemotherapy [23].
Criteria for identifying recipients at moderate to high risk of
developing platinum intolerance
Treating the patients falling under these criteria with cisplatin
requires extra caution. Some variables previously put in the con-
traindication group were switched to the high risk group following
the panel discussion, such as age, a CCR of 50–60 ml/min, a variety
of co-morbidities and social support. Other high risk factors
included a performance status score of grade 2, borderline organ
function, prior platinum-based therapy including induction
chemotherapy, weight loss, nutritional status, and concomitant
use of nephrotoxic drugs.
Discussion
Age, co-morbidity and organ dysfunctions appear to be the
most important factors that need to be considered in decision mak-
ing. Regarding special populations at increased risk of toxicity [36],
managing elderly patients, together with cognitive function and
geriatric syndromes, is a top priority for physicians to handle.ers for selection/cut-off Supporting literature/clinical
evidence
ECOG performance status scoring
[24]
Real-life clinical practice and
literature on cutoff CCR value
[23]
g hearing loss or tinnitusP grade 2 Literature on platinum-induced
ototoxicity [25]
n audible frequency (audiometric criteria:
aged at 2 contiguous test frequencies or
or intervention is not indicated)
NCI CTC criteria version 4.0 [22]
ropathy, peripheral sensory neuropathy,
rmitte’s sign, seizures, and focal
Literature on platinum-induced
neurotoxicity [22,26]
in platinum or mannitol: skin rash, flushing,
ry complications
Literature on hypersensitivity
reactions associated with
platinum agents [27]
Literature on platinum based
chemotherapy and pregnancy
[28]
nded
<200/ll WHO clinical staging of HIV/AIDS
[29]
Table 3
Finalized outputs of Group B. Clinical criteria for high risk cases.
Listing items
(physiological
system/clinical condition)
Rationale Clinical/laboratory parameters for selection/cut-off Supporting literature/clinical evidence
Performance status Poor compliance ECOG score = 2 ECOG performance status scoring [24]
Biological age No benefit from addition of
cisplatin based chemotherapy
>70 years old
Geriatric assessment
Cognitive function
Evidence from meta-analysis [3,30]
Renal dysfunction Worsening of toxicity
Risk of fluid overload or
dehydration
CCR = 50–60 ml/min
Doses < 100 mg/m2 should be considered
Real-life clinical practice and literature on
cutoff CCR value [23]
Borderline function of
target organs
–Otology
–Neurology
Worsening of toxicity NCI CTC criteria for borderline organ function:
grade 1
Medical history
Toxicity profile
NCI CTC criteria version 4.0 [22]
Dysfunction of other
organs
Presence of anemia
Hepatic impairment
Marrow, hepatic, and respiratory
dysfunctionP grade 2
Child-Pugh score = B
Toxicity profile
NCI CTC criteria version 4.0 [22]
Co-morbidities Increased risk of toxicity due to
delayed hepatic metabolism
Accelerating ageing of the kidney
Cardiovascular disease including hypertension,
unstable cardiac disease, diabetes, and recurrent
pulmonary infections
Toxicity profile
Literature on influence of hypertension and
diabetes on kidney [31,32]
HIV/AIDS or immuno-
compromised
conditions
Weakening of immune system Stage III, CD4 count <350/ll according to WHO
definition
WHO clinical staging of HIV/AIDS [29]
Previous platinum therapy
including induction
chemotherapy
Long-term cardio-toxicity,
increased risk of cumulative
toxicity, poor compliance
>200 mg/m2
>3 cycles TPF induction therapy
Toxicity/compliance profile
TREMPLIN [8], Literature on circulating
plasma platinum [21]
Weight loss and
nutritional status
Serious and dose-limiting side
effect
Involuntary weight lossP 20% Literature on influence of weight loss on
patient outcomes [33]
Concomitant use of
nephrotoxic drugs
Worsening of toxicity, altering
pharmacology of cisplatin
Medical history Literature on how concomitant use of
nephrotoxic drugs alter pharmacology of
platinum agents [34]
Socioeconomic
status/social and home
support
Toxicity and compliance History/clinical
No social support, no support at home
Toxicity profile
Literature on importance of home and social
support [35]
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tory, neurologic, cardiovascular, hepatic, and bone marrow disor-
ders. As for functional status, mostly patients with ECOG
performance status of P3 are often better served with best sup-
portive care only. We have also factored in HIV/AIDS, polyphar-
macy, hypersensitivity, pregnancy and lactation, nutritional
status, and socioeconomic issues.
Performance status is used to quantify cancer patients’ general
well-being and activities of daily life, thereby determining whether
they can receive chemotherapy or whether dose adjustment is nec-
essary. The lower compliance to chemotherapy and the fear of a
higher risk of toxicity are often noted in patients with an ECOG
score of 2 or higher. Given the concept of absolute contraindication
put forward at the meeting, an ECOG performance status graded as
2 was regarded as a high risk factor, and a grade of 3 or higher as a
contraindication.
In some countries in Asia the use of cisplatin is not recom-
mended in patients aged 75 and over. Important with respect to
the treatment of patients with LA-SCCHN is the observation in
the MACH-NC meta-analysis that no clear benefit of CCRT over
RT could be found in patients over 71 years of age [3]. However,
it was understood that this observation was not based on biological
age but calendar age. Therefore, a more comprehensive and objec-
tive assessment of the individual was felt to be more appropriate
as a selection procedure than chronological age alone, and failure
to do so may lead to suboptimal treatments being chosen with pos-
sible inferior outcomes [37]. However, the discussion on the age of
patients with LA-SCCHN is relevant not only to the point of co-
morbidities but also from the perspective of maintaining the social
and holistic impact of the patient’s performance after cure of the
disease. As noted from demographic studies, HPV positive cases
generally belong to the young working-age population, who, inaddition to having a favorable prognosis after treatment, also
contribute to the familial, societal and national productivity of a
nation. Avoiding undue residual toxicities, which may considerably
handicap normal functioning capacity, may be valuable in the long
term.
Renal dysfunction is critical as the kidney itself is of great
importance in physiologic activity, and moreover in case of
dysfunction this may lead to increased platinum levels thereby
putting patients at a higher risk of other toxicities as well as fluid
overload or dehydration. For example, nephrotoxicity was found
significantly correlating with the occurrence of ototoxicity
(P = 0.011) [19]. Assessment for signs and symptoms of fluid vol-
ume overload or deficit is also necessary. The debate revolved
around the issue of renal dysfunction at this meeting. A
compromised renal function is generally defined as a CCR of
being lower than 60 ml/min. When kidney function decreases
(CCR 40–60 ml/min), it is generally advised to reduce the dose
of cisplatin by 50% and when the CCR is less than 40 ml/min
cisplatin should be stopped.
To prevent the worsening of ototoxicity it would appear that a
CCR of <60 ml/min could be considered a relative contraindication
to cisplatin. In some countries (e.g. China), cisplatin is stopped in
SCCHN patients with a CCR of <60 ml/min, and carboplatin is used
instead for patients with a CCR of 40–60 ml/min. Platinum agents
are stopped totally when the CCR is less than 40 ml/min. However,
in Hong Kong and Korea 75% cisplatin can still be used for a CCR of
50–60 ml/min. The panel finally reached consensus on a cut-off
value of 50 ml/min as an absolute contraindication to cisplatin
based therapy to take into account the clinical practice in the
real-life setting and give balanced coverage of various opinions.
Those with a CCR of 50–60 ml/min should be treated with caution,
and doses lower than 100 mg/m2 should be considered in that
M.-J. Ahn et al. / Oral Oncology 53 (2016) 10–16 15situation. However, the consensus was to aim at achieving a cumu-
lative cisplatin dose of 200 mg/m2 during RT [38].
Based on the NCI CTC version 4.0 [22], disorders of grade 2 or
higher, including hearing impairment, tinnitus and neuropathy,
were classified as contraindications. If graded as 1, such disorders
were considered as high risk factors. It is clinical practice in China
that any adverse effects greater than grade 2 must lead to anti-
cancer chemotherapy discontinuation. Hearing tests are usually
not available in routine clinical practice, which necessitates physi-
cians’ attention to patients’ medical history regarding hearing
problems.
On the other hand, a variety of disorders of grade 2 or higher,
such as bone marrow, hepatic, and respiratory dysfunction, as well
as co-morbidities including cardiovascular disease and diabetes,
were allocated to the high risk group.
It should be noted that co-morbidities not only can increase the
risk of toxicity, drugs used to treat co-morbidities may also interact
with chemotherapeutic drugs, thereby further increasing toxicity.
Chronic systemic hypertension and diabetes mellitus can acceler-
ate ageing of the kidney, thus increasing the sensitivity of the kid-
ney to the toxic effects of cisplatin.
Toxicities resulting from bone marrow dysfunction must be cor-
rected in patients with cancer. Anemia is usually present because
of the disease or its treatment and, if left uncorrected, it can not
only alter drug activity and increase toxicity but also represent a
risk factor for decreased distribution of water-soluble drugs, car-
diovascular disease, congestive heart failure, coronary death and
possibly dementia. In addition to the NCI CTC version 4.0, the
Child-Pugh score is often used to assess the prognosis of chronic
liver disease. Hepatic impairment described as Child-Pugh grade
B may increase the risk of developing cisplatin induced toxicity.
In patients with head and neck cancer undergoing CCRT, the
early nutritional management can reduce weight loss and improve
outcome. Both nutritional deficiency and weight loss (involuntary
weight loss P20%) represent high risk to platinum based therapy.
Concomitant use of nephrotoxic drugs, another risk factor, can
affect renal blood flow and renal tubular properties, and may alter
the pharmacology of platinum agents.
Prior platinum, including prior induction chemotherapy, is
regarded as a risk factor, not only with respect to tolerance and
compliance, but also to long-term cardiovascular toxicity. It can
be expected that giving cisplatin based induction chemotherapy
before cisplatin based CCRT is leading to more toxicity because of
the subsequently increased cumulative dose of cisplatin. As men-
tioned earlier, this approach is not recommended as a standard
form of treatment in LA-SCCHN. However, induction chemother-
apy followed by different forms of locoregional treatment is get-
ting major attention in clinical trial settings, e.g. in HPV positive
oropharynx cancer [39].
People with HIV/AIDS have had a weakened immune system,
before they even start cancer treatment. Chemotherapy can further
weaken the immune system, and potentially might have a further
negative effect on the outcome. Some aspects of treatment may
need to be adjusted in people with HIV/AIDS. Based on the WHO
definition, we placed those with a CD4 count of <350/ll into the
high risk group, and agreed that cisplatin was contraindicated in
those with a CD4 count of <200/ll.
Home and social support is critical in providing patients with
valuable sources for hope in their care. Healthcare providers can
develop proactive strategies to shelter patients from the negative
aspects of cancer and chemotherapy. Lack of home and social sup-
port may therefore pose a high risk.
Also included into the contraindications were known hypersen-
sitivity to platinum based therapy and pregnancy and lactation.
The former may lead to cardiovascular and respiratory
complications that can prove fatal. As for the latter, exposure tochemotherapy after the first trimester of pregnancy is associated
with increased risk of fetal toxicities. Because of the relatively long
half-life of cisplatin, discontinuation of breastfeeding is usually
recommended.
In this paper, the recommendations for the criteria were
largely developed by synthesizing expert opinions from the Asia
Pacific Region (e.g. cutoff values for age, CCR, ECOG score, CD4
count) and mechanism based reasoning (e.g. circulating plasma
platinum, acceleration in kidney aging in diabetics). Although the
level of evidence cannot be graded as high enough, these
recommendations are still based around literature; and moreover,
such consensus statements may indicate possibilities for future
research.
As mentioned earlier, methods to reduce or avoid the toxicity of
cisplatin-based CCRT in SCCHN include better radiotherapy target-
ing [CT (computed tomography) – MRI (magnetic resonance imag-
ing) – PET (Positron emission tomography) and IGRT (image guided
radiotherapy)], new radiotherapy techniques [IMRT (intensity
modulated radiotherapy) and SW-IMRT (swallowing sparing
IMRT), stereotactic radiotherapy, and IMPT (intensity modulated
proton therapy)], and alternatives to cisplatin, such as other cyto-
toxics (carboplatin, taxanes, low-dose gemcitabine) and biological
agents (cetuximab).
Carboplatin is frequently used to replace cisplatin because of its
similar mode of action, but lower rates of ototoxicity, nephrotoxi-
city, neurotoxicity and emesis [40]. Carboplatin has also the advan-
tage of being primarily eliminated by excretion with the urine, and
therefore it can be better dosed based on glomerular filtration rate
(GFR). As such, carboplatin can also be used in a setting of dimin-
ished kidney function. Dosing based on the GFR (in practice the
CCR is used for this) according to the Calvert formula [total carbo-
platin dose (mg) = (target AUC)  (GFR + 25)] is common practice
in solid tumor treatment, and the method results in a better dosage
for individual patients than the BSA based dosing strategy [41].
However, elderly patients and those with a poor performance sta-
tus and history of extensive pretreatment still have a higher risk of
toxicity. Despite the fact that large randomized trials comparing
carboplatin and cisplatin in the CCRT setting are lacking, carbo-
platin is frequently used in routine clinical practice when cisplatin
is not tolerated or contraindicated. It should be noted that the use
of carboplatin plus RT did not result in overall survival improve-
ment versus RT alone in the MACH-NC meta-analysis [3]. Despite
the fact that more contemporary studies suggest it might be a rea-
sonable option when cisplatin is contraindicated, adequate trials
supporting this notion are urgently needed.
On the other hand, cetuximab is a synergistic chemosensitizer
and radiosensitizer, as observed from preclinical and several clini-
cal studies [7,42]. Treatment adherence of >90% with cetuximab
plus RT seems better than that with cisplatin-based CCRT, with
no impact on quality of life as compared with RT alone [7,43].
However, as mentioned earlier, there has been no definitive
answer as to whether cetuximab can replace cisplatin in CCRT
because no direct head-to-head comparison of chemoradiation
and bioradiation in phase III has been reported. Studies in that
direction are under way.Conclusion
Based on literature review and panel discussion, the Expert
Panel succeeded in developing a set of clinical criteria for defining
platinum unsuitable patient populations with head and neck can-
cer, which could be applied to clinical practice. In case of platinum
ineligibility, replacing cisplatin with other (less toxic) cytotoxic
agents or cetuximab may be taken into consideration. Trials are
under way to generate stronger supporting data.
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